Deans' stroke musings: Inflammation and Stroke Risk: A New Target for Prevention

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Saturday, June 26, 2021

Inflammation and Stroke Risk: A New Target for Prevention

Since we are not given a public location where this info is located you are completely reliant on your doctor having access to this, reading it, creating a protocol on it, and prescribing that protocol to you. DO YOU TRUST YOUR DOCTOR TO DO THOSE SIMPLE TASKS?

Inflammation and Stroke Risk: A New Target for Prevention

Peter J. Kelly

Robin Lemmens

Georgios Tsivgoulis

Originally published24 Jun 2021https://doi.org/10.1161/STROKEAHA.121.034388Stroke. ;0:STROKEAHA.121.034388

Abstract

New therapeutic approaches are required for secondary prevention of residual vascular risk after stroke. Diverse sources of evidence support a causal role for inflammation in the pathogenesis of stroke. Randomized controlled trials of anti-inflammatory agents have reported benefit for secondary prevention in patients with coronary disease. We review the data from observational studies supporting a role for inflammation in pathogenesis of stroke, overview randomized controlled trials of anti-inflammatory therapy in cardiac disease and discuss the potential implications for stroke prevention therapy.